Narayana Hrudayalaya revenues recovered to 96% of pre Covid levels, largely in line with our expectations.

Chirag Batavia • 15 February 2021

Narayana Hrudayalaya (NARH)

 In Q3FY21, NARH revenues recovered to 96% of pre Covid levels, largely in line with our expectations.

 Cayman unit sustained its strong performance recording 30% yoy growth benefiting from increased footfalls of local patients, increased focus on the outpatient segment and recalibration of prices.

 NARH’s execution at Gurugram and Dharamshila, particularly in oncology has also been impressive with units breaking even ahead of guidance.

 With the international segment gradually recovering, decline in Covid cases driving improvement in patient mix and improving maturity profile, India business remains on a strong footing.

 With performance improving across segments, we expect NARH to deliver 20% RoCE by FY23E with robust Free Cash Flow.

 We revise our FY22-23E EBITDA by 9-11% to bake in faster breakeven at new units and strong Cayman performance and valuing the stock at 18X FY23E EBITDA.


Narayana Hrudayalaya (NARH): BUY
Dated: 15th February 2021
CMP: Rs.460
Fair Value: Rs.540
Potential Upside: 17.4%
Market Cap: Rs. 9400 Cr
Time Frame: 12 months

Note: The above is a brief note on the company, based on the inputs of KIE research report dated 9th February 2021, which is available on their website at: https://www.kotaksecurities.com/ksweb/ResearchCall/Fundamental.      
Disclaimer: http://bit.ly/2n5AxIE




Looking to invest in Narayana Hrudayalaya and other Indian stocks? Open your trading account with Lakshit Financial

Lakshit Financial Authorized Person of Kotak Securities Limited in cash segments of BSE & NSE and NSE F&O segments with NSE. Lakshit Financial registration number: BSE CASH AP0106730124228 | NSE CASH AP029177621 | NSE F&O AP029177621.Registered Office: Lakshit Financial, ASM 7, Ashwin Sector, Mumbai Agra Highway, CIDCO, Nasik 422009, Maharashtra, India. Kotak Securities Limited. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. CIN: U99999MH1994PLC134051. SEBI Registration No. INZ000200137 (Member of NSE, BSE, MSE, MCX & NCDEX). Member Id: NSE-08081; BSE-673; MSE-1024; MCX-56285; NCDEX-1262. AMFI ARN 0164, PMS INP000000258 and Research Analyst INH000000586. NSDL/CDSL: IN-DP-NSDL-23-97.

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please refer the Risk Disclosure Document issued by SEBI and go through the Rights and Obligations and Do's and Dont's issued by Stock Exchanges and Depositories before trading on the Stock Exchanges.

DID YOU KNOW, as an NR I , you can invest in IPOs and purchase shares, ETFs or convertible debentures of an Indian company through stock exchanges. All it takes is linking your NRO or NRE account to an active Demat account in India on a repatriable or non-repatriable basis, based on your requirements. Click here to learn more about NRI Trading and Demat Accounts.

OPEN YOUR ACCOUNT NOW !

Fill in your details and we will get in touch with you.

Products and services available only for People of Indian Origin

Note:  Please note that by submitting the above mentioned details, you are authorising Lakshit Financial to call you and send promotional communication even though you may be registered under DNC. Also, all calls with Lakshit Financial representatives may be recorded for internal quality & training purposes

This is a subtitle for your new post

The body content of your post goes here. To edit this text, click on it and delete this default text and start typing your own or paste your own from a different source.

Looking to invest in HOME FIRST FINANCE (HOMEFIRST) and other Indian stocks? Open your NRI Demat Acc
30 December 2024
Home First Finance (HOMEFIRST) Home First remains consistent on operational and financial parameters. Home First (HFFC) reported 24% earnings growth, with 19% net interest income growth in Q2FY25. Gross stage-3 ratio was flat qoq at 1.7%, stage-2 ratio declined 6 bps qoq to 1.1%. While other asset classes have reported mixed trends residential home loans, as an asset class, continues to stand tall. Home First, with 85% home loan exposure, is well-placed on the above. We expect the company to deliver 25% earnings CAGR for FY25-27E. We remain assertive with a BUY rating and FV of Rs1,360 (no change). Note: The above is a brief note on the company, based on the inputs of KIEresearch report dated 25111Oct, 2024, which is available onour website at: https://www.kotaksecurities.com/ksweb/ResearchCall/Fundamenta1. Disclaimer: http://bit.ly/2n5Ax1E https://www.kotaksecurities.oom/ksweb/research/kotak-research-reports/top-weekly-picks
More posts
Share by:
gtag('config', 'AW-634979631');